Matt is a Director in Deloitte’s Global Investment and Innovation Incentives (Gi3) team with key expertise in clinical innovation. Leveraging a background in Medical Science and as a Chartered Accountant, Matt has extensive experience in advising Life Sciences companies in accessing the Australian clinical landscape and R&D Tax Incentives.
Matt is also the chair of the BioNSW Commercialisation Committee, a national Research and Development Taskforce member, and was previously awarded the top specialist consultant in Australia in the Accountants Daily 30 under 30 awards.